Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Fierce Pharma6d
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
NBC Washington8d
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Shares of Zealand Pharma jumped 38%, while Roche shares closed 3.6% higher. Shares of obesity drug giant Novo Nordisk, meanwhile, slipped 4.3% during Wednesday's session. Zealand Pharma CEO and ...